Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma
By
Ming Yao
Xavier Cheng-Hong Tsai
Chung-Wu Lin
Shu-Lang Liao
Cheng-Ping Wang
Wei-Li Ma
Yi-Hsuan Wei
Hsiao-Wei Lee
Jyh-Ming Liou
Wei-Li Chen
I-Jong Wang
Ann-Lii Cheng
Sung-Hsin Kuo
May 29, 2026
Clinical Scorecard: Phase II Trial Investigating Initial Helicobacter pylori Eradication Treatment for Early-Stage Extragastric Mucosa-Associated Lymphoid Tissue Lymphoma
At a Glance
Category Detail
Condition Key Mechanisms Helicobacter pylori eradication (HPE) regimens (source needed) Target Population Patients with localized extragastric MALT lymphoma (source needed) Care Setting
Key Highlights
Overall response rate (ORR) of 65.4% in 26 patients (source needed) Complete remission (CR) achieved in 38.5% of patients (source needed) Median duration of lymphoma-free survival was 78.8 months for CR patients (source needed) 7-year event-free survival rate of 76.5% (source needed) 7-year overall survival rate of 95.8% (source needed) Guideline-Based Recommendations
Diagnosis
HP infection confirmed by 13C-urea breath test, serology test, or histology (source needed) Management
Frontline HPE regimens including lansoprazole, amoxicillin, clarithromycin, and metronidazole (source needed) Monitoring & Follow-up
Follow-up every 3 months for PR or stable disease; every 6 months for CR (source needed) Risks
Potential progression of lymphoma if no tumor shrinkage is observed (source needed) Patient & Prescribing Data
26 patients with localized extragastric MALT lymphoma
Sequential HPE regimens resulted in significant response rates
Clinical Best Practices
Regular follow-ups with imaging studies for monitoring (source needed) Consider second-line treatments for patients with stable disease or progression (source needed) Related Resources & Content
